Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | September 26, 2014

Trends and New Data at TCT 2014

By Dave Fornell, editor of DAIC Magazine

The key take away messages from the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium were bioresorable stents and transcatheter valve technologies will likely become primary interventional tools in the near future. These two areas were among the hottest topics of discussion in sessions, live case presentations, late-breaking trials and on the expo floor. The latest trial data for both technologies presented at TCT continue to show extremely positive trends in patient outcomes that are equal or better than current standards of therapy. 

Key news on bioresorbable stents at the meeting came from the ABSORB II Trial, which compared the Abbott Absorb BVS drug-eluting bioresorbable stent to the company's market-leading Xience metalic drug-eluting stent. At one year the clinical outcomes were the same, but the bioresorbable stent patients reported a significantly lower incidence of angina. This opens up an entirely new avenue of research into these devices and their potential benefits. This inspired changes in the upcoming ABSORB IV trial to examine angina outcomes specifically. Watch a video discussing these findings and the future of bioresorbable stents. 

There were several trial presentations of transcatheter aortic valve replacement (TAVR), including long-term outcomes and economic impact of using these devices (see news items below). One of the key issues with TAVR has been stroke rates higher than surgical valve replacements, and three start-up companies showed cerebral embolic protection devices at TCT. The biggest news in this area was from a trial involving the Claret device, which resulted in a lower stroke rate. Here is an article overview of the TAVR embolic protection devices in development

I attended one packed, standing-room-only session on transcatheter mitral valve replacement devices in development. This is definitely the next technology area to watch, as I suspect this will become the next major technology highlighted at future ACC and TCT meetings.

I highlighted the details of two technologies that may offer paradigm shifts in interventional cardiology in the next couple years in a video about intravascular imaging to detect vulnerable plaque, and a video about CT-FFR.

There were many cutting-edge technologies highlighted at TCT. I offer a roundup of these in my video "DAIC Editor's Choice of the Most Innovative New Technologies at TCT 2014."

 

Related Content

Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Medtronic Shares Two-Year Harmony Transcatheter Pulmonary Valve Results at SCAI 2018. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
Medtronic plc announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Colibri Heart Valve Continues Enrollment in TAVI Early Feasibility Study
News | Heart Valve Technology | May 07, 2018
Colibri Heart Valve LLC announced the Colibri transcatheter aortic valve implantation (TAVI) System has been used on an...
An 3D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

A 3-D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

Feature | Heart Valve Technology | May 04, 2018 | Dave Fornell, Editor
May 4, 2018 — Transcatheter val...
Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy - Cardioband Tricuspid Valve Reconstruction System
News | Heart Valve Technology | May 01, 2018
Edwards Lifesciences Corp.announced that it received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction...
Overlay Init